SMTL ID : 7nxj.2 (1 other biounit)

Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.36 Å

Oligo State

hetero-1-1-mer

Ligands

1 x 5I1: N-[4-[(3R)-3-[[5-chloranyl-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonylphenyl]-4-(dimethylamino)butanamide(Covalent)

5I1.1: 20 residues within 4Å: Chain A: I.16, I.18, I.19, E.21, V.27, K.29, A.40, K.42, I.73, F.99, E.100, Y.101, M.102, D.103, H.104, D.105, L.152, D.163, Q.323, C.325 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:I.16, A:I.19, A:I.19, A:V.27, A:D.105, A:L.152 Hydrogen bonds: A:I.18, A:K.42, A:M.102, A:M.102, A:D.163, A:Q.323

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Jiang, B. et al., Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur.J.Med.Chem. (2021)

Release Date

2021-05-12

Peptides

Cyclin-dependent kinase 13: A
Cyclin-K: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

Cyclin-dependent kinase 13

Cyclin-K

Related Entries With Identical Sequence